Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007704 | 1.00 | CTDSP1 (0.33) | CTDSP1MEN1KMT2ASLC18A3HTR6 | |
| SCHEMBL6641164 | 0.98 | CTDSP1 (0.34) | CTDSP1HTR6 | |
| SCHEMBL735596 | 0.98 | CTDSP1 (0.34) | CTDSP1HTR6 | |
| SCHEMBL738719 | 0.93 | CTDSP1 (0.34) | CTDSP1 | |
| SCHEMBL2009169 | 0.93 | SLC18A3 (0.31) | CTDSP1SLC18A3 | |
| SCHEMBL736119 | 0.93 | SLC18A3 (0.31) | CTDSP1SLC18A3 | |
| SCHEMBL204448 | 0.93 | HTR6 (0.31) | CTDSP1HTR6 | |
| SCHEMBL735469 | 0.90 | CTDSP1 (0.31) | CTDSP1 | |
| SCHEMBL738778 | 0.90 | — | — | |
| SCHEMBL14343220 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | claimed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | claimed |
| EP-2727919-B1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-9296731-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2016-03-29 | — | — | US | disclosed |
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | disclosed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | disclosed |
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-12-07 | — | — | US | disclosed |
| WO-2006119646-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1569929-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS | Virochem Pharma Inc. (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
| WO-2004052885-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CTDSP1 3908/4885MEN1 3705/4885KMT2A 1784/4885 |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | NR1H4, TST, CYP7A1 | CTDSP1 2052/4885MEN1 4669/4885KMT2A 1143/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | CTDSP1 3690/4885MEN1 2904/4885KMT2A 528/4885 |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | TST, HRH1, ABCB11 | CTDSP1 1726/4885MEN1 4563/4885KMT2A 1580/4885 |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, YBX1, HAX1 | CTDSP1 2118/4885MEN1 1088/4885KMT2A 3282/4885 |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | NR1H4, TST, CYP7A1 | CTDSP1 2052/4885MEN1 4669/4885KMT2A 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.